Real-world data confirms that the favorable safety profile of CAR T-cell therapies like Obicell holds true in broad clinical practice. This has been a crucial factor in expanding eligibility to older patients, with successful treatments now being administered to individuals in their 70s and 80s.

Moving CAR T-cell therapy to earlier treatment lines is crucial. This approach targets cancer before it develops resistance and, more importantly, utilizes patient T-cells that are healthier and more effective, not having been damaged by extensive prior chemotherapy regimens.

For third-line follicular lymphoma, where both CAR-T and bispecifics are approved, experts are leaning towards CAR-T. The long-term follow-up data for CAR-T suggests a potential for cure, making it a more compelling option for eligible patients despite logistical challenges.

Despite FDA warnings, the actual risk of developing a secondary T-cell lymphoma after CAR-T for lymphoma is exceedingly rare. Experts contextualize this as an anecdotal risk for a potentially curative therapy, with baseline germline abnormalities possibly predisposing some patients.

The efficacy of Siltacel stems from a powerful initial expansion that eliminates cancer upfront. The CAR-T cells are often undetectable beyond six months, indicating their curative potential comes from an overwhelming initial response rather than persistent, long-term immune policing of the disease.

Five-year follow-up from the CARTITUDE-1 trial suggests a potential cure for multiple myeloma is achievable. With roughly one-third of heavily pretreated patients remaining in remission at five years—and some confirmed as MRD-negative—the concept of a cure is now part of the operational discussion among specialists, a monumental shift for a disease long considered incurable.

Traditional age cutoffs for AML therapy are becoming obsolete. A comprehensive fitness assessment, not just chronological age, should guide treatment, as some guidelines now classify patients as young as 55 as "older adults," a surprising shift for many clinicians.

Contrary to typical findings where real-world data underperforms, liso-cel CAR T-cell therapy in CLL demonstrates significantly better outcomes in practice than in its approval trial (over 80% response rate vs. under 50%). This suggests that using the therapy earlier in healthier, less-refractory patients unlocks its true potential.

The next major shift for CAR T-cell therapy is its integration into frontline treatment. Instead of being reserved for relapse, it's being tested as a consolidation therapy that could replace the standard two to three years of maintenance chemotherapy, dramatically shortening treatment duration.